Stoke Therapeutics Chief Scientific Officer Thomas McCauley files initial beneficial ownership statement

Stoke Therapeutics filed an initial Form 3 with the SEC on July 17, 2026, disclosing beneficial ownership for Chief Scientific Officer Thomas McCauley. The filing, dated July 13, 2026, was published via EDGAR (Ref ID: 0001858760-26-000007). This information is generated by Public Technologies using AI and is for informational purposes only.

Stoke Therapeutics filed an initial Form 3 naming Thomas McCauley as chief scientific officer, dated July 13, 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Stoke Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001858760-26-000007), on July 17, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here